דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים: CareDx, Inc (CDNA)

CareDx, Inc (CDNA) products in the maturity phase are facing pressure from Medicare, as evidenced by the TTM revenue growth dynamics. The value 39.30 represents the latest reading for this trend level. The business is based on non-invasive donor-derived cell-free DNA monitoring of transplants for the early diagnosis of rejection. The system's efficiency is complemented by express logistics for biomaterials, ensuring high delivery speeds and operational resilience.
caredx.com - פילוחים אנליטיים ומדדי מפתח (CDNA)

CareDx, Inc (CDNA) specialization in transplant patient monitoring makes its revenue dependent on the scaling of diagnostic services and the implementation of IT solutions. The year-over-year sales volume growth trajectory for the TTM reflects the dynamics of total receipts over a rolling year, allowing investors to filter out short-term fluctuations and assess real demand for the company's products to confirm the sustainability of its market capitalization.